Mike Serrano-Wu, Ph.D.
Chief Scientific Officer
Michael Serrano-Wu has been a key driver for several first-in-class drug discovery efforts. At BMS, he catalyzed the nascent field of HCV NS5A-based therapy by designing the first known palindromic inhibitor, leading to the discovery of daclatasvir and an entire class of follow-on drugs. Later at Novartis, Mike led the team which discovered pradigastat, a DGAT1 inhibitor currently in clinical investigation.
Mike received his A.B. and Ph.D. in Organic Chemistry from Harvard University.